Stem cell research leads to potential new therapy for rare blood disorder

A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia. In just one year, collaborative discoveries by stem cell researchers from the University of California, San Diego, Dana-Farber Cancer Institute, the Mayo Clinic and a San Diego pharmaceutical company, TargeGen, moved from identification of the most promising drug candidate to clinical trials for a new drug to fight this degenerative blood disorder, which affects more than 100,000 Americans.

A study headed by Catriona H.M. Jamieson, M.D. Ph.D., assistant professor of medicine at the University of California, San Diego and Director for Stem Cell Research at Moores UCSD Cancer Center, found an inhibitor that can stop the over-proliferation of blood cells that results in problems with blood clotting, heart attacks and, in some cases, leukemia. Funded in part by a grant from the California Institute for Regenerative Medicine (CIRM), the study will be published in Cancer Cell on April 8, 2008. A parallel study at Harvard Medical School, headed by D. Gary Gilliland, Ph.D., M.D., yielded similar results which will appear in the same issue of Cancer Cell.

“As a clinician, I asked myself who is going to get this disease, and what can we do to stop its progression, instead of waiting until it evolves into a deadly cancer?” said Jamieson. “This project has been so extraordinary, because a small pharmaceutical company took a big chance on a rare disease.”

With major contributions from collaborators Jason Gotlib at Stanford University and Ayalew Tefferi at the Mayo Clinic, the research findings led to development of the inhibitor by TargeGen. That drug is currently being tested in human clinical trials at the UC San Diego School of Medicine, the Mayo Clinic, M.D. Anderson Cancer Center, and the University of Michigan, Stanford and Harvard University Schools of Medicine.

A patient with MPD makes too many blood cells, caused by a mutation expressed in the stem cell, the early stage cell that goes on to differentiate to become either red or white blood cells. In 2006, Jamieson was first author on a paper published in PNAS, outlining the discovery that a mutation in the JAK2 signaling pathway in patients with a type of MPD called polycythemia vera (PV) allows cells to bypass the process which would normally regulate the production of red blood cells. As a result of this defect, the bone marrow produces excessive numbers of red blood cells.

In the current research described in Cancer Cell, the UCSD School of Medicine researchers and collaborators transferred human cord blood stem cells, engineered to contain the mutant JAK2 gene, into mouse models with a suppressed immune system to find whether over-expression of a single gene could drive, or initiate, the disease. These stem cells were introduced directly into the liver, the main site of blood development in the newborn mouse. As a result, the stem cells over-expressing the mutant gene led to overproduction of human red blood cells, and the mice developed a disease that looked like PV.

The researchers corroborated these results by injecting actual stem cells from patients with PV into the same mouse model, achieving similar results. “We found that the JAK2 mutation was necessary and sufficient, by itself, to drive the disease,” Jamieson said.

Theorizing that blocking this mutation would prevent overproduction of red blood cells, TargeGen developed a selective JAK2 inhibitor called TG101348. This therapy was shown in animal studies to halt over-expression of the gene and reverse excessive production of red blood cells. Because TG101348 selectively targets the JAK2 protein that causes the disease, side effects have been minimized.

“Pre-clinical testing at the UCSD and Harvard University Schools of Medicine confirmed the therapeutic potential of TG101348. The compound was rapidly advanced into the current, ongoing human clinical trials being conducted at major research institutions across the country,” said John Hood, Ph.D., Director of Research for TargeGen. “This unique industry-academia collaboration has helped guide a new drug from bench to bedside, from evaluating the compound’s efficacy on cancer stem cells to its evaluation in patients bearing a disease which otherwise has very limited treatment options.”

Source: University of California - San Diego

Related stories:

Researchers devise means to create blood by identifying earliest stem cells
Johns Hopkins researchers have discovered the earliest form of human blood stem cells and deciphered the mechanism by which these embryonic stem cells replicate and grow. They also found a surprising biological marker that pinpoints these stem cells, which serve as the progenitors for red blood cells and lymphocytes.
Blood vessel cells are instructed to form tube-like structures
How do blood vessel cells understand that they should organise themselves in tubes and not in layers? A research group from Uppsala University shows for the first time that a special type of "instructor" molecule is needed to accomplish this. These findings, published in the scientific journal Blood, might be an important step towards using stem cells to build new organs.
Researchers turn one form of adult mouse cell directly into another
(PhysOrg.com) -- In a feat of biological prestidigitation likely to turn the field of regenerative medicine on its head, Harvard Stem Cell Institute (HSCI) co-director Doug Melton and post doctoral fellow Qiao "Joe" Zhou report having achieved what has long been a dream and ultimate goal of developmental biologists – directly turning one type of fully formed adult cell into another type of adult cell.
Bone marrow stem cells may help control inflammatory bowel disease
Massachusetts General Hospital (MGH) investigators have found that infusions of a particular bone marrow stem cell appeared to protect gastrointestinal tissue from autoimmune attack in a mouse model. In their report published in the journal Stem Cells, the team from the MGH Center for Engineering in Medicine report that mesenchymal stem cells (MSCs), known to control several immune system activities, allowed the regeneration of the gastrointestinal lining in mice with a genetic mutation leading to multiorgan autoimmune disease.
Stem cells can be used to create limitless blood supplies: paper
Scientists from a US firm claim to have created a large number of red blood cells from human embryonic stem cells, opening up the prospect of having a limitless supply of blood for transfusions.
Researcher develops novel method to grow human embryonic stem cells
(PhysOrg.com) -- The majority of researchers working with human embryonic stem cells (hESCs) – cells which produce any type of specialized adult cells in the human body – use animal-based materials for culturing the cells. But because these materials are animal-based, they could transmit viruses and other pathogens to the hESCs, making the cells unsuitable for medical use.
Biomarkers reveal our biological age
(PhysOrg.com) -- Not a day passes when we don’t get a little bit older. However, the exact processes involved in human aging are still puzzling. Scientists working with Lenhard Rudolph and Hong Jiang from the Max Planck Research Group for Stem Cell Aging in Ulm have now identified a group of proteins that reveal the biological age of a person. These biomarkers could be used in medicine to adapt therapies for older people to their individual biological age (PNAS, August 12, 2008).
Stem cell advance may help transfusion supplies
(AP) -- Scientists say they've found an efficient way to make red blood cells from human embryonic stem cells, a possible step toward making transfusion supplies in the laboratory.

News discussion:

Medicine & Health news